Pomegra
UK biotech Neobe raised €6.1M in a seed round led by ARC Ventures to advance engineered bacteria that dissolve tumour barriers toward a 2028 IND filing.
Key Takeaways
- Neobe raised €6.1M ($6.8M, £5M) in a seed round led by ARC Ventures, announced November 10, 2026.
- Lead candidate NEO22 targets an IND filing in 2028; total funding now exceeds €9.4M.
- Valuation was not disclosed.
Lead
Neobe Therapeutics, a Stevenage-based company founded in 2021, has raised €6.1M ($6.8M, or £5M) in seed funding to develop bacteria that clear the dense matrix around solid tumours. The round, announced on November 10, 2026, was led by ARC Ventures. It brings the company's cumulative funding to more than €9.4M ($10.5M). The money is meant to carry its lead programme, NEO22, through preclinical work toward an investigational new drug application in 2028.
Who Backed the Round?
ARC Ventures led, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures. Existing backer 2048 Ventures followed on. Neobe did not disclose a valuation.
A €6.1M seed for a company already four years old is a measured raise by therapeutics standards. It signals that investors are funding a defined preclinical package rather than a broad platform build-out. The company also named Dr Laura Chow as chief medical officer, and it plans to expand its leadership team ahead of a first-in-human trial.
What Does Neobe Actually Make?
Neobe engineers harmless bacterial strains that colonise tumours and release enzymes which degrade the fibrous extracellular matrix surrounding them. The lead programme uses hyaluronidase to break down hyaluronan, a matrix component that helps shield tumours from drugs and immune cells.
The bacteria do not kill cancer cells directly. They are designed to open the tumour up so that existing treatments, particularly immunotherapies, can reach their targets. Genetic circuits keep the enzyme production switched off until the bacteria are inside the tumour, which is meant to limit activity in healthy tissue.
The approach would sit alongside, not replace, checkpoint inhibitors and similar drugs. Its commercial case therefore depends on partnering with, or being layered onto, therapies that already work in some patients and fail in others.
What Do the Preclinical Results Show?
In a 2026 paper in Molecular Cancer Therapeutics, Neobe and collaborators at the University of Cyprus and Barts Cancer Institute in London tested the platform in a model of triple-negative breast cancer that did not respond to a standard immunotherapy combination. A single dose of the engineered bacteria, combined with immunotherapy, produced complete tumour regression. According to the company, no recurrence appeared months later.
Those are mouse-model data, and the gap between a regression in rodents and a response in people is wide in oncology. Bacterial therapies add their own questions on immune reactions, dosing consistency and manufacturing. The company's CEO and co-founder, Dr Pedro Correa de Sampaio, framed the problem as access: "Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed."
Why Does the Tumour Barrier Matter?
Solid tumours are often walled off by dense stroma, and that limits how far drugs and T cells can penetrate. Immunotherapy has produced durable responses in some cancers, yet a large share of solid-tumour patients do not benefit. Neobe's pitch is that a physical barrier, rather than a lack of drug potency, explains part of that failure.
Other groups are pursuing the same idea with enzymes, stromal-targeting drugs and engineered microbes. None of this is settled. Earlier attempts to deplete tumour stroma have sometimes backfired, so showing that matrix breakdown helps rather than harms in humans is the central scientific risk.
What Comes Next for Neobe?
The near-term work is preclinical: building the toxicology, manufacturing and safety package needed for an IND application, which Neobe targets for 2028. A first-in-human trial would follow, and the company will need more capital to run it. The seed does not cover clinical costs, so a larger Series A is the logical next step if NEO22 holds up in further animal studies.
Investors will watch for data in additional tumour models and for evidence that the genetic circuits behave reliably at scale. A pharma partner interested in boosting its own immunotherapy would be the most direct route to validation, though no such deal has been announced.
Outlook
Neobe has secured enough funding to push NEO22 to the doorstep of the clinic, backed by a lead investor and a single, striking mouse dataset. The 2028 IND target is the next hard milestone, and the open questions are safety, reproducibility and whether stroma-busting translates to patients. Until human data arrive, the story remains a well-funded hypothesis with encouraging early evidence.
